154 related articles for article (PubMed ID: 9140677)
1. Ambulatory blood pressure monitoring in patients with essential hypertension treated with a new calcium antagonist, cilnidipine.
Tominaga M; Ohya Y; Tsukashima A; Kobayashi K; Takata Y; Koga T; Yamashita Y; Fujishima Y; Abe I; Fujishima M
Cardiovasc Drugs Ther; 1997 Mar; 11(1):43-8. PubMed ID: 9140677
[TBL] [Abstract][Full Text] [Related]
2. Effects of cilnidipine, a novel dihydropyridine calcium antagonist, on autonomic function, ambulatory blood pressure and heart rate in patients with essential hypertension.
Minami J; Kawano Y; Makino Y; Matsuoka H; Takishita S
Br J Clin Pharmacol; 2000 Dec; 50(6):615-20. PubMed ID: 11136301
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.
Hoshide S; Kario K; Ishikawa J; Eguchi K; Shimada K
Hypertens Res; 2005 Dec; 28(12):1003-8. PubMed ID: 16671340
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory blood pressure monitoring in elderly hypertensives treated with the new calcium antagonist, pranidipine (OPC-13340).
Tominaga M; Tsuchihashi T; Kinoshita H; Kobayashi K; Ohya Y; Abe I; Takata Y; Fujishima M
Int J Clin Pharmacol Ther; 1995 May; 33(5):277-80. PubMed ID: 7655766
[TBL] [Abstract][Full Text] [Related]
5. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients.
Kitahara Y; Saito F; Akao M; Fujita H; Takahashi A; Taguchi H; Hino T; Otsuka Y; Kushiro T; Kanmatsuse K
J Cardiovasc Pharmacol; 2004 Jan; 43(1):68-73. PubMed ID: 14668570
[TBL] [Abstract][Full Text] [Related]
6. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
7. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.
Kario K; Ando S; Kido H; Nariyama J; Takiuchi S; Yagi T; Shimizu T; Eguchi K; Ohno M; Kinoshita O; Yamada T
J Clin Hypertens (Greenwich); 2013 Feb; 15(2):133-42. PubMed ID: 23339732
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.
Minami J; Ishimitsu T; Kawano Y; Numabe A; Matsuoka H
J Cardiovasc Pharmacol; 1998 Aug; 32(2):331-6. PubMed ID: 9700998
[TBL] [Abstract][Full Text] [Related]
9. Comparison between cilnidipine and nisoldipine with respect to effects on blood pressure and heart rate in hypertensive patients.
Minami J; Ishimitsu T; Higashi T; Numabe A; Matsuoka H
Hypertens Res; 1998 Sep; 21(3):215-9. PubMed ID: 9786607
[TBL] [Abstract][Full Text] [Related]
10. Effects of a dual L/N-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension.
Kai T; Kuzumoto Y
Clin Exp Hypertens; 2009 Oct; 31(7):595-604. PubMed ID: 19886857
[TBL] [Abstract][Full Text] [Related]
11. Effect of a novel calcium channel blocker on abnormal nocturnal blood pressure in hypertensive patients.
Kario K; Nariyama J; Kido H; Ando S; Takiuchi S; Eguchi K; Niijima Y; Ando T; Noda M
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):465-72. PubMed ID: 23815534
[TBL] [Abstract][Full Text] [Related]
12. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.
Kanaoka T; Tamura K; Wakui H; Ohsawa M; Azushima K; Uneda K; Kobayashi R; Fujikawa T; Tsurumi-Ikeya Y; Maeda A; Yanagi M; Toya Y; Umemura S
Int J Mol Sci; 2013 Aug; 14(8):16866-81. PubMed ID: 23959116
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
Takei K; Araki N; Ohkubo T; Tamura N; Yamamoto T; Furuya D; Yanagisawa CT; Shimazu K
Intern Med; 2009; 48(16):1357-61. PubMed ID: 19687579
[TBL] [Abstract][Full Text] [Related]
14. Effects of benidipine hydrochloride on 24-hour blood pressure and blood pressure response to mental stress in elderly patients with essential hypertension.
Muneta S; Kohara K; Hiwada K
Int J Clin Pharmacol Ther; 1999 Mar; 37(3):141-7. PubMed ID: 10190762
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension.
Yamagishi T
Hypertens Res; 2006 May; 29(5):339-44. PubMed ID: 16832154
[TBL] [Abstract][Full Text] [Related]
16. Reduction of white coat effect by cilnidipine in essential hypertension.
Morimoto S; Takeda K; Oguni A; Kido H; Harada S; Moriguchi J; Itoh H; Nakata T; Sasaki S; Nakagawa M
Am J Hypertens; 2001 Oct; 14(10):1053-7. PubMed ID: 11710785
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of manidipine on circadian blood pressure in essential hypertension.
Nakamura T; Honma H; Kohno I; Tsuruta I; Ishii H; Tamura K
Blood Press Suppl; 1992; 3():94-101. PubMed ID: 1343299
[TBL] [Abstract][Full Text] [Related]
18. Prolonged hypotensive effect of OPC-13340: a new, once-daily calcium channel blocking drug.
Broadhurst P; Brigden G; Hittel N; Lahiri A; Raftery EB
Eur Heart J; 1991 Mar; 12(3):434-8. PubMed ID: 2040326
[TBL] [Abstract][Full Text] [Related]
19. Bedtime administration of cilnidipine controls morning hypertension.
Ashizawa N; Seto S; Shibata Y; Yano K
Int Heart J; 2007 Sep; 48(5):597-603. PubMed ID: 17998769
[TBL] [Abstract][Full Text] [Related]
20. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring.
Stergiou GS; Malakos JS; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 1997 Mar; 29(3):412-6. PubMed ID: 9125681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
